XML 55 R40.htm IDEA: XBRL DOCUMENT v3.20.4
Overview - Schedule of Restatement of Previously Issued Consolidated Financial Statements (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2020
Dec. 31, 2019
Jul. 15, 2019
Cash and cash equivalents             $ 15,106 $ 2,321  
Accounts receivable, net of allowance for doubtful accounts             7,239 10,338  
Other current assets             3,751 3,851  
Total current assets             26,096 16,510  
Property and equipment, net             7,249 6,814  
Other intangible assets, net             13,619 15,849  
Goodwill             8,433 8,433 $ 8,300
Operating lease right of use assets             5,172    
Other long-term assets             42 42  
Total assets             60,611 51,540  
Accounts payable             3,348 4,709  
Accrued salary and bonus             2,247 2,341  
Other accrued expenses             9,737 9,476  
Current liabilities from discontinued operations             766 766  
Total current liabilities             16,098 17,292  
Contingent consideration             2,207 2,391  
Operating lease liabilities, net of current portion             3,940 2,591  
Line of credit             3,400 3,000  
Other long-term liabilities             4,557 4,573  
Total liabilities             30,202 29,847  
Commitments and contingencies (Note 8)              
Preferred stock value              
Common stock value             402 393  
Additional paid-in capital             182,980 182,514  
Accumulated deficit             (197,739) (185,665)  
Treasury stock, at cost (11,781 shares)             (1,770) (1,721)  
Total stockholders' equity $ 6,838 $ 6,838 $ 13,346 $ 32,938 $ (16,127) $ 32,938 (16,127) (4,479)  
Total liabilities and stockholders' equity             14,075 25,368  
Total liabilities, preferred stock and stockholders' equity             60,611 51,540  
Revenue, net 5,446   6,270   14,504 12,280      
Cost of revenue 3,850   3,031   9,963 5,654      
Gross profit 1,596   3,239   4,541 6,626      
Sales and marketing 1,596   2,959   4,077 5,369      
Research and development 550   647   1,360 1,175      
General and administrative 4,107   2,788   8,999 5,122      
Acquisition related expense   1,295   1,696      
Acquisition related amortization expense 1,115   897   2,230 1,794      
Total operating expenses 7,368   8,586   16,666 15,156      
Operating loss (5,772)   (5,347)   (12,125) (8,530)      
Interest accretion (167)   (91)   (276) (220)      
Other income (expense), net 438   74   485 123      
Loss from continuing operations before tax (5,501)   (5,364)   (11,916) (8,627)      
Provision for income taxes 13   5   28 10      
Loss from continuing operations, net of tax (5,514)   (5,369)   (11,944) (8,637)      
Less adjustment for preferred stock deemed dividend     3,033      
Loss from continuing operations attributable to common stockholders (5,580)   (5,304)   (12,074) (8,630)      
Loss from discontinued operations, net of tax (66)   65   (130) 7      
Net loss attributable to common stockholders $ (5,580)   $ (5,304)   $ (15,107) $ (8,630)      
From continuing operations $ (1.37)   $ (1.41)   $ (3.73) $ (2.36)      
From discontinued operations (0.01)   0.02   (0.03)      
Net loss per basic and diluted share of common stock $ (1.38)   $ (1.39)   $ (3.76) $ (2.36)      
Basic 4,033,000   3,813,000   4,018,000 3,665,000      
Diluted 4,033,000   3,813,000   4,018,000 3,665,000      
Balance $ 6,838 (4,479) $ 35,771 32,938 $ (4,479) $ 32,938      
Common stock issued 1 73 1          
Restricted stock issued              
Common stock issued through market sales   484            
Common stock issued through offerings     5,962          
Treasury stock purchased (49) (32)          
Extinguishment of Series A Shares   (828)            
Beneficial Conversion Feature in connection with Series B Issuance   2,205            
Amortization of Beneficial Conversion Feature   (2,205)            
Stock-based compensation expense 400 418 205 266          
Adoption of ASC 842     55          
Net loss (5,580) (6,494) (5,304) (3,419) (15,107) (8,630)      
Balance (16,127) 6,838 13,346 35,771 (16,127) 13,346      
Net loss         (12,074) (8,630)      
Depreciation and amortization         2,708 1,917      
Interest accretion         276 220      
Mark to market on warrants         (49) (45)      
Stock-based compensation 818   500   818 990      
Bad debt expense         250 499      
Other gains and expenses, net         0 18      
Decrease (increase) in accounts receivable         2,849 (3,982)      
(Increase) decrease in other current assets         (788) (252)      
(Decrease) increase in accounts payable         (1,361) 530      
(Decrease) increase in accrued salaries and bonus         (94) (261)      
(Decrease) increase in accrued liabilities         759 1,097      
Increase in long-term liabilities         33 114      
Net cash used in operating activities         (6,673) (7,785)      
Purchase of property and equipment         (913) (48)      
Sale of property and equipment         0 13      
Net cash provided by investing activity         (913) (35)      
Issuance of common stock, net of expenses         434 5,962      
Borrowings on Line of Credit, net         400      
Issuance of Series B preferred stock, net of expenses         19,537      
Net cash provided by financing activities         20,371 5,962      
Net increase (decrease) in cash and cash equivalents         12,785 (1,858)      
Cash and cash equivalents - beginning   2,321 5,377 6,068 2,321 6,068      
Cash and cash equivalents - ending 15,106   4,210 5,377 15,106 4,210      
Common Stock [Member]                  
Total stockholders' equity 402 402 383 382 402 383 402 393  
Balance $ 402 $ 393 $ 382 $ 287 $ 393 $ 287      
Balance, shares 4,055,000 3,932,000 3,819,000 2,877,000 3,932,000 2,877,000      
Common stock issued $ 1 $ 1 $ 1          
Common stock issued, shares 37,000 10,000 9,000          
Restricted stock issued              
Restricted stock issued, shares   6,000            
Common stock issued through market sales   $ 8            
Common stock issued through market sales, shares   80,000            
Common stock issued through offerings     $ 94          
Common stock issued through offerings, shares     933          
Treasury stock purchased          
Treasury stock purchased, shares          
Extinguishment of Series A Shares              
Beneficial Conversion Feature in connection with Series B Issuance              
Amortization of Beneficial Conversion Feature              
Stock-based compensation expense          
Adoption of ASC 842            
Net loss          
Balance $ 402 $ 402 $ 383 $ 382 $ 402 $ 383      
Balance, shares 4,055,000 4,055,000 3,829,000 3,819,000 4,055,000 3,829,000      
Treasury Stock [Member]                  
Total stockholders' equity $ (1,721) $ (1,721) $ (1,712) $ (1,712) $ (1,770) $ (1,712) (1,770) (1,721)  
Balance $ (1,721) $ (1,721) $ (1,712) $ (1,680) $ (1,721) $ (1,680)      
Balance, shares 12,000 12,000 10,000 7,000 12,000 7,000      
Common stock issued          
Common stock issued, shares          
Restricted stock issued              
Restricted stock issued, shares              
Common stock issued through market sales              
Common stock issued through market sales, shares              
Common stock issued through offerings              
Common stock issued through offerings, shares              
Treasury stock purchased $ (49) $ (32)          
Treasury stock purchased, shares 7,000 3,000          
Extinguishment of Series A Shares              
Beneficial Conversion Feature in connection with Series B Issuance              
Amortization of Beneficial Conversion Feature              
Stock-based compensation expense          
Adoption of ASC 842            
Net loss          
Balance $ (1,770) $ (1,721) $ (1,712) $ (1,712) $ (1,770) $ (1,712)      
Balance, shares 19,000 12,000 10,000 10,000 19,000 10,000      
Additional Paid-in Capital [Member]                  
Total stockholders' equity $ 182,580 $ 182,580 $ 182,231 $ 181,954 $ 182,980 $ 182,231 182,980 182,514  
Balance 182,580 182,514 181,954 175,820 182,514 175,820      
Common stock issued 72          
Restricted stock issued              
Common stock issued through market sales   476            
Common stock issued through offerings     5,868          
Treasury stock purchased          
Extinguishment of Series A Shares   (828)            
Beneficial Conversion Feature in connection with Series B Issuance   2,205            
Amortization of Beneficial Conversion Feature   (2,205)            
Stock-based compensation expense 400 418 205 266          
Adoption of ASC 842              
Net loss          
Balance 182,980 182,580 182,231 181,954 182,980 182,231      
Accumulated Deficit [Member]                  
Total stockholders' equity (192,159) (192,159) (167,556) (162,252) (197,739) (167,556) (197,739) (185,665)  
Balance (192,159) (185,665) (162,252) (158,981) (185,665) (158,981)      
Common stock issued          
Restricted stock issued              
Common stock issued through market sales              
Common stock issued through offerings              
Treasury stock purchased          
Extinguishment of Series A Shares              
Beneficial Conversion Feature in connection with Series B Issuance              
Amortization of Beneficial Conversion Feature              
Stock-based compensation expense          
Adoption of ASC 842     55          
Net loss (5,580) (6,494) (5,304) (3,326)          
Balance (197,739) (192,159) (167,556) (162,252) $ (197,739) (167,556)      
Series B [Member]                  
Preferred stock value             46,536  
Common stock issued, shares         27,000        
As Previously Reported [Member]                  
Cash and cash equivalents             15,106    
Accounts receivable, net of allowance for doubtful accounts             7,239    
Other current assets             3,751    
Total current assets             26,096    
Property and equipment, net             7,249    
Other intangible assets, net             31,439    
Goodwill             8,433    
Operating lease right of use assets             5,172    
Other long-term assets             42    
Total assets             78,431    
Accounts payable             3,348    
Accrued salary and bonus             2,247    
Other accrued expenses             9,737    
Current liabilities from discontinued operations             766    
Total current liabilities             19,498    
Contingent consideration             2,207    
Operating lease liabilities, net of current portion             3,940    
Line of credit             3,400    
Other long-term liabilities             4,557    
Total liabilities             30,202    
Commitments and contingencies (Note 8)                
Common stock value             402    
Additional paid-in capital             182,980    
Accumulated deficit             (179,919)    
Treasury stock, at cost (11,781 shares)             (1,770)    
Total stockholders' equity 6,838 6,838     $ 1,693   1,693    
Total liabilities and stockholders' equity             31,895    
Total liabilities, preferred stock and stockholders' equity             78,431    
Revenue, net 5,446   6,270   14,645 12,280      
Cost of revenue 3,850   3,031   9,963 5,654      
Gross profit 1,596   3,239   4,682 6,626      
Sales and marketing 1,596   2,959   4,077 5,369      
Research and development 550   647   1,360 1,175      
General and administrative 4,107   2,788   8,993 5,299      
Acquisition related expense   1,295   1,696      
Acquisition related amortization expense 1,031   813   2,062 1,626      
Total operating expenses 7,284   8,502   16,492 15,165      
Operating loss (5,688)   (5,263)   (11,810) (8,539)      
Interest accretion (167)   (91)   (276) (220)      
Other income (expense), net 438   74   485 123      
Loss from continuing operations before tax (5,417)   (5,280)   (11,601) (8,636)      
Provision for income taxes 13   5   28 10      
Loss from continuing operations, net of tax (5,430)   (5,285)   (11,629) (8,646)      
Less adjustment for preferred stock deemed dividend     (3,033)      
Loss from continuing operations attributable to common stockholders (5,430)   (5,285)   (14,662) (8,646)      
Loss from discontinued operations, net of tax (66)   65   (130) 7      
Net loss attributable to common stockholders $ (5,496)   $ (5,220)   $ (14,792) $ (8,639)      
From continuing operations $ (1.35)   $ (1.39)   $ (3.65) $ (2.36)      
From discontinued operations (0.01)   0.02   (0.03)      
Net loss per basic and diluted share of common stock $ (1.36)   $ (1.37)   $ (3.68) $ (2.36)      
Basic 4,033,000   3,813,000   4,018,000 3,665,000      
Diluted 4,033,000   3,813,000   4,018,000 3,665,000      
Balance $ 6,838                
Balance 1,693 6,838     $ 1,693        
Net loss         (11,759) $ (8,639)      
Depreciation and amortization         2,540 1,749      
Interest accretion         276 220      
Mark to market on warrants         (49) (45)      
Stock-based compensation         818 990      
Bad debt expense         250 499      
Other gains and expenses, net         18      
Decrease (increase) in accounts receivable         2,708 (3,982)      
(Increase) decrease in other current assets         (788) (252)      
(Decrease) increase in accounts payable         (1,464) 530      
(Decrease) increase in accrued salaries and bonus         (94) (141)      
(Decrease) increase in accrued liabilities         856 1,154      
Increase in long-term liabilities         33 114      
Net cash used in operating activities         (6,673) (7,785)      
Purchase of property and equipment         (913) (48)      
Sale of property and equipment         13      
Net cash provided by investing activity         (913) (35)      
Issuance of common stock, net of expenses         434 5,962      
Borrowings on Line of Credit, net         400      
Issuance of Series B preferred stock, net of expenses         19,537      
Net cash provided by financing activities         20,371 5,962      
Net increase (decrease) in cash and cash equivalents         12,785 (1,858)      
Cash and cash equivalents - beginning   2,321 $ 5,377 6,068 2,321 6,068      
Cash and cash equivalents - ending 15,106   4,210 5,377 15,106 4,210      
As Previously Reported [Member] | Common Stock [Member]                  
Total stockholders' equity 402 402 383 382 393 383   393  
Balance $ 402 $ 393 $ 382 $ 287 $ 393 $ 287      
Balance, shares 4,055,000 3,932,000 3,819,000 2,877,000 3,932,000 2,877,000      
Common stock issued   $ 1 $ 1 $ 1          
Common stock issued, shares   37,000 10,000 9,000          
Restricted stock issued              
Restricted stock issued, shares   6,000            
Common stock issued through market sales   $ 8            
Common stock issued through market sales, shares   80,000            
Common stock issued through offerings     $ 94          
Common stock issued through offerings, shares     933,000          
Balance   $ 402 $ 383 $ 382   $ 383      
Balance, shares   4,055,000 3,829,000 3,819,000   3,829,000      
As Previously Reported [Member] | Treasury Stock [Member]                  
Total stockholders' equity $ (1,770) $ (1,721) $ (1,712) $ (1,712) $ (1,770) $ (1,712) (1,770) (1,721)  
Balance $ (1,721) $ (1,721) $ (1,712) $ (1,680) $ (1,721) $ (1,680)      
Balance, shares 12,000 12,000 10,000 7,000 12,000 7,000      
Treasury stock purchased $ (49)   $ (32)          
Treasury stock purchased, shares 7,000   3,000          
Balance $ (1,770) $ (1,721) $ (1,712) $ (1,712) $ (1,770) $ (1,712)      
Balance, shares 19,000 12,000 10,000 10,000 19,000 10,000      
As Previously Reported [Member] | Additional Paid-in Capital [Member]                  
Total stockholders' equity $ 182,980 $ 182,580 $ 182,231 $ 181,954 $ 182,980 $ 182,231 182,980 182,514  
Balance 182,580 182,514 181,954 175,820 182,514 175,820      
Common stock issued     72            
Common stock issued through market sales   476            
Common stock issued through offerings     5,868          
Extinguishment of Series A Shares   (828)            
Beneficial Conversion Feature in connection with Series B Issuance   2,205            
Amortization of Beneficial Conversion Feature   (2,205)            
Stock-based compensation expense 400 418 205 266          
Balance 182,980 182,580 182,231 181,954 182,980 182,231      
As Previously Reported [Member] | Accumulated Deficit [Member]                  
Total stockholders' equity (179,919) (174,423) (150,073) (141,489) (179,919) (150,073) (179,919) (168,160)  
Balance (174,423) (168,160) (144,853) (141,489) (168,160) (141,489)      
Adoption of ASC 842     55          
Net loss (5,496) (6,263) (5,220) (3,419)          
Balance (179,919) (174,423) (150,073) (144,853) (179,919) (150,073)      
As Previously Reported [Member] | Series B [Member]                  
Preferred stock value             46,536    
Restatement Amount [Member]                  
Cash and cash equivalents                
Accounts receivable, net of allowance for doubtful accounts                
Other current assets                
Total current assets                
Property and equipment, net                
Other intangible assets, net             (17,820)    
Goodwill                
Operating lease right of use assets                
Other long-term assets                
Total assets             (17,820)    
Accounts payable                
Accrued salary and bonus                
Other accrued expenses                
Current liabilities from discontinued operations                
Total current liabilities                
Contingent consideration                
Operating lease liabilities, net of current portion                
Line of credit                
Other long-term liabilities                
Total liabilities                
Commitments and contingencies (Note 8)                
Common stock value                
Additional paid-in capital                
Accumulated deficit             (17,820)    
Treasury stock, at cost (11,781 shares)                
Total stockholders' equity (17,736) (17,736)     (17,820)   (17,820)    
Total liabilities and stockholders' equity             (17,820)    
Total liabilities, preferred stock and stockholders' equity             (17,820)    
Revenue, net     (141)      
Cost of revenue          
Gross profit     (141)      
Sales and marketing          
Research and development          
General and administrative     6 (177)      
Acquisition related expense          
Acquisition related amortization expense 84   84   168 168      
Total operating expenses 84   84   174 (9)      
Operating loss (84)   (84)   (315) 9      
Interest accretion          
Other income (expense), net          
Loss from continuing operations before tax (84)   (84)   (315) 9      
Provision for income taxes          
Loss from continuing operations, net of tax (84)   (84)   (315) 9      
Less adjustment for preferred stock deemed dividend          
Loss from continuing operations attributable to common stockholders (84)   (84)   (315) 9      
Loss from discontinued operations, net of tax          
Net loss attributable to common stockholders $ (84)   $ (84)   $ (315) $ 9      
From continuing operations $ (0.02)   $ (0.02)   $ (0.08) $ 0.00      
From discontinued operations          
Net loss per basic and diluted share of common stock $ (0.02)   $ (0.02)   $ (0.08)      
Basic 4,033,000   3,813,000   4,018,000 3,665,000      
Diluted 4,033,000   3,813,000   4,018,000 3,665,000      
Balance $ (17,736)                
Balance (17,820) (17,736)     $ (17,820)        
Net loss         (315) $ 9      
Depreciation and amortization         168 168      
Interest accretion              
Mark to market on warrants              
Stock-based compensation              
Bad debt expense              
Other gains and expenses, net              
Decrease (increase) in accounts receivable         141      
(Increase) decrease in other current assets              
(Decrease) increase in accounts payable         103      
(Decrease) increase in accrued salaries and bonus         (120)      
(Decrease) increase in accrued liabilities         (97) (57)      
Increase in long-term liabilities              
Net cash used in operating activities              
Purchase of property and equipment              
Sale of property and equipment              
Net cash provided by investing activity              
Issuance of common stock, net of expenses              
Borrowings on Line of Credit, net              
Issuance of Series B preferred stock, net of expenses              
Net cash provided by financing activities              
Net increase (decrease) in cash and cash equivalents              
Cash and cash equivalents - beginning        
Cash and cash equivalents - ending        
Restatement Amount [Member] | Common Stock [Member]                  
Total stockholders' equity      
Balance        
Common stock issued              
Restricted stock issued                
Restricted stock issued, shares                
Common stock issued through market sales                
Common stock issued through offerings                
Balance                
Restatement Amount [Member] | Treasury Stock [Member]                  
Total stockholders' equity    
Balance      
Balance, shares            
Treasury stock purchased              
Balance              
Balance, shares                
Restatement Amount [Member] | Additional Paid-in Capital [Member]                  
Total stockholders' equity    
Balance        
Common stock issued through market sales                
Common stock issued through offerings                
Extinguishment of Series A Shares                
Beneficial Conversion Feature in connection with Series B Issuance                
Amortization of Beneficial Conversion Feature                
Stock-based compensation expense              
Balance            
Restatement Amount [Member] | Accumulated Deficit [Member]                  
Total stockholders' equity (17,820) (17,736) (17,483) (17,492) (17,820) (17,483) (17,820) $ (17,505)  
Balance (17,736) (17,505) (17,399) (17,492) (17,505) (17,492)      
Adoption of ASC 842              
Net loss (84) (231) (84) 93          
Balance $ (17,820) $ (17,736) $ (17,483) $ (17,399) $ (17,820) $ (17,483)      
Restatement Amount [Member] | Series B [Member]                  
Preferred stock value